Irish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
chronic pain/ailse
Sábháiltear an nasc chuig an gearrthaisce
Leathanach 1 ó 46 torthaí
Levobupivacaine for managing chronic pain
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION
This invention relates to a new therapeutic use for a known analgesic agent, i.e. bupivacaine or 1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide.
BACKGROUND OF THE INVENTION
Racemic bupivacaine, a long-acting local anaesthetic, is useful in chronic administration as an
Compositions and methods for the treatment of chronic pain
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
PRIORITY
The present application claims the benefit of Indian Provisional Patent Application No. 1857/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/051482 filed on 24 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into
Drug for the effective control of acute and or chronic pain and a method for its administration
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a U.S. national stage application of an international application PCT/SG2017/050210 filed on 13 Apr. 2017, published as WO/2017/180064, whose disclosure is incorporated herein in its entirety by reference, which international application
Human antibodies to GFR .alpha.3 and methods of treating pain associated with osteoarthritis or bone cancer
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION
The present invention is related to human antibodies and antigen-binding fragments of human antibodies that specifically bind to human glial cell-line derived neurotrophic factor (GDNF) family receptor alpha 3 (GFR.alpha.3), and therapeutic methods of using those
Extended release hydrocodone acetaminophen and related methods and uses thereof
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND
A patient's quality of life is adversely affected by pain. Further, this quality of life is associated with loss of work productivity, which impacts both the patient and its employer adversely.
Thus, for example, moderate to severe pain and physical disability that are symptoms of
Nitroxyl (HNO) releasing compounds and uses thereof in treating diseases
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
Nitroxyl (HNO) is an elusive chemical species that has been shown to possess intriguing biological properties. For example, nitroxyl has been implicated in the mechanism of cyanamide's inhibitory effect on aldehyde dehydrogenase in treating alcohol abuse as well as
Use of cobratoxin as an analgesic
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a protein composition of matter and a method for the treatment of chronic pain, especially to the treatment of heretofore intractable pain as associated with advanced cancer. The pain associated with neurological
Multivalent clostridial toxins
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
The ability of Clostridial toxins to inhibit neuronal transmission are being exploited in a wide variety of therapeutic and cosmetic applications, see e.g., William J. Lipham, Cosmetic and Clinical Applications of Botulinum Toxin (Slack, Inc., 2004). Clostridial toxins commercially available as
Multivalent Clostridial toxin derivatives and methods of their use
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
The present invention is drawn to multivalent Clostridial neurotoxin derivatives having more than one binding domain directed to a cell surface feature of a target cell.
The ability of Clostridial toxins, such as, e.g., Botulinum neurotoxins (BoNTs), BoNT/A, BoNT/B, BoNT/C1, BoNT/D, BoNT/E, BoNT/F
Multivalent clostridial toxins
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
The ability of Clostridial toxins to inhibit neuronal transmission are being exploited in a wide variety of therapeutic and cosmetic applications, see e.g., William J. Lipham, Cosmetic and Clinical Applications of Botulinum Toxin (Slack, Inc., 2004). Clostridial toxins commercially available as
6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
The invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as
6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
The invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as
1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
The invention relates to 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S related diseases such as atherosclerosis,
Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
This invention relates to compounds and methods for treating prostaglandin E mediated diseases, and certain pharmaceutical compositions thereof. More particularly, the compounds of the invention are structurally different from NSAIDs and opiates, and are antagonists of
1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND
The present invention relates to 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione derivatives, to pharmaceutical compositions comprising the same and to the use of these 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione derivatives in therapy, especially in the treatment of pain.
Pain is an
An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht
- Oibreacha i 55 teanga
- Leigheasanna luibhe le tacaíocht ón eolaíocht
- Aitheantas luibheanna de réir íomhá
- Léarscáil GPS idirghníomhach - clibeáil luibheanna ar an láthair (ag teacht go luath)
- Léigh foilseacháin eolaíochta a bhaineann le do chuardach
- Cuardaigh luibheanna míochaine de réir a n-éifeachtaí
- Eagraigh do chuid spéiseanna agus fanacht suas chun dáta leis an taighde nuachta, trialacha cliniciúla agus paitinní
Clóscríobh symptom nó galar agus léigh faoi luibheanna a d’fhéadfadh cabhrú, luibh a chlóscríobh agus galair agus comharthaí a úsáidtear ina choinne a fheiceáil.
* Tá an fhaisnéis uile bunaithe ar thaighde eolaíoch foilsithe
